New combo therapy targets Hard-to-Treat cancers
NCT ID NCT07566897
First seen May 09, 2026 · Last updated May 09, 2026
Summary
This early-stage trial tests a new combination of two drugs (L19IL2 and ruxolitinib) in people with advanced kidney, pancreatic, or colorectal cancers that have stopped responding to standard treatments. The main goals are to find a safe dose and check for side effects. About 96 participants will be enrolled. This is not a cure, but aims to control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fondazione Policlinico Gemelli Unità di Fase 1: Unità di Farmacologia Clinica
Roma, Roma, 00168, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.